BioNTech

Anthropic

Biotech

Anthropic is a San Francisco AI-safety and research company, founded in 2021 by former OpenAI researchers led by siblings Dario and Daniela Amodei, that develops the Claude family of large language models. As of mid-August 2026 its lineup spans Claude Haiku 4.5, Claude Sonnet 5, the everyday-default Claude Opus 5 (which replaced Opus 4.8 on July 24), and its most capable widely released model, Claude Fable 5 (plus the invitation-only Claude Mythos 5). Claude reaches customers through the claude.ai apps, the Claude API, enterprise and government plans, and Claude Code - its agentic coding tool, which runs at a $2.5B+ run-rate with 2M+ weekly active users - alongside the Claude Cowork 'AI coworker' and the June 2026 Claude Science research workbench, built on the ~$400M acqui-hire of ex-Genentech drug-discovery startup Coefficient Bio, that positions Anthropic in AI-driven pharma R&D. Anthropic differentiates on safety and interpretability research and runs one of the industry's largest multi-vendor compute footprints spanning Amazon (Project Rainier; Amazon's committed capital reached $33B in April 2026), Google (TPUs, up to $40B plus a 3.5 GW Broadcom-built expansion), AMD, CoreWeave, and newer data-center leases with TeraWulf, Riot Platforms and Volta Infra - and was reported on August 13, 2026 to be in talks to acquire AI-infrastructure startup Decart for roughly $6B. Annualized run-rate revenue topped $65B as of late July 2026 (up from ~$47B in May and ~$9B at the end of 2025; some IPO investors are modeling $100-120B by year-end), more than 1,000 customers now spend over $1M/year, and preliminary Q2 2026 revenue exceeded $11.5B with its first profitable quarter since founding. In May 2026 it raised a $65B Series H at a $965B valuation (secondary markets have since priced it above $1T-$1.2T) and confidentially filed for an IPO in June 2026; CFO Krishna Rao is now holding early investor meetings for a possible fall listing that some backers are modeling near a $2T valuation, though Anthropic itself has not set a target. On August 27, 2026 a San Francisco federal judge (Rita Lin) ruled the Pentagon's supply-chain-risk designation of Anthropic unlawful as First Amendment retaliation and arbitrary and capricious, writing that the measures were illegal and baseless; a separate D.C. Circuit case over a second designation remains pending, and the government is expected to appeal. The same day Anthropic opened a research preview of the Model Hardware Standard (MHS), a model-agnostic specification started with HHMI Janelia that lets AI agents operate lab and manufacturing hardware such as microscopes, liquid handlers and robotic arms, with a plan to open-source the standard after the preview.

CRISPR Therapeutics

Biotech

CRISPR Therapeutics is a gene-editing pioneer co-founded in 2013 by Nobel laureate Emmanuelle Charpentier - co-inventor of CRISPR/Cas9 - alongside Rodger Novak and Shaun Foy. Its flagship, Casgevy (exagamglogene autotemcel), is the world's first approved CRISPR/Cas9 gene-editing medicine: a one-time therapy for sickle cell disease and transfusion-dependent beta thalassemia, developed and commercialized with Vertex Pharmaceuticals (which books the sales; CRISPR keeps ~40% of the economics). Casgevy is now approved across 9+ jurisdictions, priced at ~$2.2M per treatment, and in July 2026 the FDA expanded its US label to children as young as two. Commercial uptake has been slower than hoped - constrained by cell-collection bottlenecks - but cumulative patient starts have surpassed 500. Beyond Casgevy, CRISPR is pivoting toward in vivo liver gene editing (cardiovascular programs CTX310 and CTX320), allogeneic CAR-T for autoimmune disease and cancer (zugo-cel/CTX112, now also being tested with Lilly's pirtobrutinib in aggressive B-cell lymphomas), and type 1 diabetes, where a next-generation deviceless beta-cell replacement candidate, CTX213, is progressing toward the clinic on the strength of durable C-peptide data from its predecessor CTX211. It has also expanded beyond gene editing into RNA interference through a 2025 collaboration with Sirius Therapeutics on CTX611 (SRSD107), a long-acting Factor XI siRNA for thromboembolic disorders now in Phase 2, with topline data due in H2 2026. In its Q2 2026 update (August 3, 2026) it reported $2,364.4M in cash and investments, a narrowed net loss of $91.2M, and the start of Phase 1 trials for two next-wave in vivo candidates, CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency, the first program from its new SyNTase editing platform), pairing a historic scientific position with a still-nascent commercial ramp.

Google DeepMind

Biotech

Google DeepMind is Alphabet's consolidated artificial-intelligence research lab, formed in April 2023 by merging the original DeepMind (founded in London in 2010, acquired by Google in 2014) with Google Brain. Co-founder and Nobel laureate Demis Hassabis stepped down as CEO on August 5, 2026, moving to Chair of Google DeepMind and Chief Scientist of Alphabet to focus on long-term AGI research and Isomorphic Labs; Koray Kavukcuoglu, an SVP reporting directly to Sundar Pichai, now runs day-to-day operations and the Gemini roadmap. The lab builds the Gemini family of frontier multimodal models - which powers the Gemini app (900M+ monthly active users as of mid-2026), Google Search's AI Mode and AI Overviews, Google Cloud's Vertex AI, and, via a 2026 partnership, Apple's next-generation Siri. Beyond consumer AI, DeepMind pioneered game-playing systems (AlphaGo, AlphaZero) and scientific breakthroughs including AlphaFold - whose protein-structure database has been used by 3M+ researchers and earned Hassabis and John Jumper the 2024 Nobel Prize in Chemistry - plus AlphaGenome, AlphaEvolve, Veo and Genie world models, and Gemini Robotics. Its drug-discovery spinout Isomorphic Labs is preparing first-in-human oncology trials. The August leadership change follows a stretch of talent departures (Jumper among them) and delays shipping Gemini 3.5 Pro, and coincided with Google chief scientist Jeff Dean also leaving the company after 27 years.

Moderna

Biotech

Moderna is the pioneer and, with BioNTech, one of the two global leaders in messenger-RNA (mRNA) medicine. Founded in 2010 and incubated by Flagship Pioneering, it rose to prominence with Spikevax, its COVID-19 vaccine that reached full FDA approval in 2022 and drove roughly $18B of revenue at its 2022 peak. Moderna is now navigating a steep post-COVID transition: FY2025 revenue fell ~40% to $1.9B and it posted a $2.8B net loss, prompting ~$2.2B of annual cost cuts and a 10% workforce reduction. The company is rebuilding around a four-product respiratory franchise - next-gen COVID vaccine mNEXSPIKE, RSV vaccine mRESVIA, Europe's first flu+COVID combination mCOMBRIAX, and, as of its August 5, 2026 FDA approval, mFlusiva, the first mRNA-based flu vaccine - while its highest-value bet is intismeran autogene (mRNA-4157/V940), an individualized neoantigen cancer therapy partnered with Merck that has shown durable five-year benefit in melanoma and, as of August 19, 2026, met both endpoints of its pivotal Phase 3 melanoma trial, with a regulatory filing planned within months. Its first rare-disease candidate, propionic acidemia therapy mRNA-3927 (partnered with Recordati since early 2026), is in a fully enrolled registrational study with data expected in 2026. With ~$6.9B in cash, 36 development programs, and a targeted return to cash-flow breakeven in 2028, Moderna is a validated-platform leader working through significant near-term financial and execution headwinds.

Oklo

Biotech

Oklo is developing fast-fission power plants under its Aurora product line while building a vertically integrated nuclear business around power sales, fuel recycling, and radioisotopes. Aurora units are designed to produce 15-75 MWe and run on fresh, recycled, or down-blended fuel, targeting customers such as data centers, industrial sites, military facilities, utilities, and remote communities. Its first plant, Aurora-INL at Idaho National Laboratory, is advancing under DOE's Reactor Pilot Program - the DOE approved its Preliminary Documented Safety Analysis on June 11, 2026, leaving the final Documented Safety Analysis as the last safety-basis step before authorization. Oklo is deepening vertical integration through the June 2026 acquisitions of Oak Ridge precision manufacturer ARMEC and sodium-systems engineering firm Creative Engineers, plus its May 2026 selection for DOE's Surplus Plutonium Utilization Program, while Atomic Alchemy builds U.S. isotope supply around the Groves test reactor in Lockhart, Texas, which reached first criticality on August 5, 2026.

TAE Technologies

Biotech

TAE Technologies is a private fusion company developing hydrogen-boron fusion with a beam-driven field-reversed-configuration architecture. Its 2025 'Norm' breakthrough reduced reactor complexity enough to skip the planned Copernicus step and move directly toward Da Vinci, its first prototype power plant. In 2026 TAE completed its multi-state site evaluation tour for the first 50 MWe plant (Alabama, Ohio, Texas), formally established the TAE Beam UK joint venture with UKAEA at Culham to commercialize neutral-beam accelerator technology, and is now targeting a Q4 2026 close of its $6B all-stock merger with Trump Media & Technology Group, which in June 2026 confirmed it will no longer spin off Truth Social and other media assets ahead of the deal. TAE Power Solutions and TAE Life Sciences commercialize adjacent power-delivery and oncology technologies derived from its fusion R&D.